Evaluation of Xpert MTB/RIF Ultra assay for rapid diagnosis of pulmonary and extra-pulmonary tuberculosis in an Italian center
Publication date: Available online 31 July 2020Source: Biosensors and BioelectronicsAuthor(s): Divagar M, Ramakrishna Bandaru, Vani Janakiraman, V.V.R. Sai
Publication date: November 2020Source: Urology Case Reports, Volume 33Author(s): Astrid Kristina Kardani, Krisni Subandiyah
Publication date: Available online 3 August 2020Source: The Lancet Respiratory MedicineAuthor(s): Claire Keene, Erika Mohr-Holland, Tali Cassidy, Vera Scott, Aurelie Nelson, Jennifer Furin, Laura Triviño-Duran
Publication date: October 2020Source: Biomedicine &Pharmacotherapy, Volume 130Author(s): P.C. de Souza, G.F.S. Fernandes, L.B. Marino, C.M. Ribeiro, P.B. da Silva, M. Chorilli, C.S.P. Silva, F.A. Resende, M.C. Solcia, R.A. de Grandis, C.A.S. Costa, S.H. Cho, Y. Wang, S.G. Franzblau, J.L. dos Santos, F.R. Pavan
[TB Alliance] PRETORIA (3 August 2020)--Pretomanid, a novel compound developed by the non-profit organization TB Alliance, has been granted a conditional marketing authorisation by the European Commission (EC) for treating highly drug-resistant forms of pulmonary tuberculosis (TB).[i] The new drug was authorised as part of a three-drug, six month, all-oral regimen for the treatment of adults with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive
Religions for Peace Interreligious Council of Albania distributing Covid relief supplies from the Multi-religious Humanitarian Fund. Credit: Erzen CarjaBy Prof. Azza KaramNEW YORK, Aug 4 2020 (IPS) — I have never been interested in religion or spirituality before, but I found myself tuning in to all sorts of on-line religion and spirituality related forums “in search of something.” These are the words of a 30-something single young, middle class man (born into a Protestant-Catholic family background) in a European country. The latter is known more for turning several churches into museums or shopping ce...
Contributors : JunFa Xu ; ZeGang Zhuang ; JunAi Zhang ; HouLong Luo ; GanBin Liu ; YuanBin Lu ; NanHai Ge ; BiYing Zheng ; RuiXi Li ; Chen Chen ; Xin Wang ; YuQing Liu ; FengHui Liu ; Yong Zhou ; XiaoZhen Cai ; ZhengW ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensIt has been reported that circular RNA (circRNA) is associated with human cancer. However, few studies have been reported in active pulmonary tuberculosis (APTB). The global circRNA expression was detected in the peripheral blood mononuclear cells (PBMCs) of APTB patients (n=5) and healthy controls (HC) (n=5) by using h...
Tuberculosis kills 1.5 million people each year. Lockdowns and supply-chain disruptions threaten progress against the disease as well as H.I.V. and malaria.
Population-wide tolerance and persisters enable susceptible bacterial cells to endure hostile environments, including antimicrobial exposure. The SOS response can play a significant role in the generation of persister cells, population-wide tolerance, and shielding. The SOS pathway is an inducible DNA damage repair system that is also pivotal for bacterial adaptation, pathogenesis, and diversification. In addition to the two key SOS regulators, LexA and RecA, some other stressors and stress responses can control SOS factors. Bacteria are exposed to DNA-damaging agents and other environmental and intracellular factors, incl...
Conclusion: Helping patients to achieve full adherence to TB medication is a complex problem as it is influenced by interplay between many factors. Healthcare managers, providers, and researchers need to consider and address multiple underlying factors when designing adherence interventions. This work provides a reference set of such factors for Ethiopian interventions.